Sodium ferric gluconate complex
Appearance
(Redirected from Ferrlecit)
Clinical data | |
---|---|
Trade names | Ferrlecit |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614030 |
License data | |
Routes of administration | Intravenous (IV) |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C66H121Fe2NaO65 |
Molar mass | 2089.309 g·mol−1 |
3D model (JSmol) | |
| |
|
Sodium ferric gluconate complex, sold under the brand name Ferrlecit, is an intravenously administered iron medication for the treatment of iron deficiency anemia in adults and in children aged six years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy.[2] The macromolecule has an apparent molecular weight of 289,000–440,000 Dalton.[3][4]
The most common side effects in adults are nausea, vomiting and/or diarrhea, injection site reaction, hypotension, cramps, hypertension, dizziness, dyspnea, chest pain, leg cramps, and pain.[2] In children the most common side effects are hypotension, headache, hypertension, tachycardia and vomiting.[2]
References
[edit]- ^ "Sodium ferric gluconate complex Use During Pregnancy". Drugs.com. 16 December 2019. Retrieved 2 April 2020.
- ^ a b c "Ferrlecit- sodium ferric gluconate complex injection". DailyMed. 25 September 2019. Retrieved 2 April 2020.
- ^ "Sodium ferric gluconate complex". www.drugbank.ca. Retrieved 21 June 2020.[title missing]
- ^ Fishbane S, Wagner J (May 2001). "Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis". American Journal of Kidney Diseases. 37 (5): 879–83. doi:10.1016/s0272-6386(05)80001-0. PMID 11325667.